Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and all areas of life sciences research. Shareholders of Harris & Harris Group, Inc., may be interested to read Metabolon's press release, "Metabolon & Baylor College of Medicine Partner to Launch Global... | January 3, 2021 Cancel. Real-time trade and investing ideas on Metabolon, Inc. BOLON from the largest community of traders and investors. GUT, the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market. Summary Metrics. Metabolon, Inc. BOLON. Most stock quote data provided by BATS. Jonathan Block, Associate Editor U.S. Food and Drug Administration (FDA) Galera Therapeutics Inc. Aridis Pharmaceuticals Inc. Palladio Biosciences Inc. Metabolon Inc.... Read More. Log In. GUT, the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market. Rohan F Hastie is President/CEO at Metabolon Inc. See Rohan F Hastie's compensation, career history, education, & memberships. GUT collection device," said Scott Rabuka, Senior Director, Molecular Products at DNA Genotek, Inc. This round of financing included Perceptive Advisors as a … Sign Up. Eric A Button is Senior VP:Diagnostics at Metabolon Inc. See Eric A Button's compensation, career history, education, & memberships. 13.12 Metabolon, Inc. Other Related Market Research Reports: Biopreservation Market Size is Projected to be AroundUS$ 4.50 Billion By 2022. Stock Summary; Articles; BioCentury | Oct 11, 2019. GUT collection device," said Scott Rabuka , Senior Director, Molecular Products at DNA Genotek, Inc. It offers biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon, Inc. Watch . Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio...CEO post. Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has filed a patent infringement lawsuit against Stemina Biomarker Discovery, Inc. in the US District Court for the Western District of Wisconsin. Company News. Metabolon - The latest news about Metabolon from the WSJ MoneyBeat Blog. Metabolon Debuts New Client Portal at Bio-IT World Expo MetaboLync™:A Cloud-based Solution for Sharing, Visualizing, and Analyzing Metabolomics Data RESEARCH TRIANGLE PARK, N.C., Apr 29, 2014 (BUSINESS WIRE) — Metabolon, Inc., a leader in metabolomics-driven biomarker discovery, announced today the debut and impending launch of MetaboLync, the company’s innovative product offering … Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, today announced the close on $72 million in combined debt and equity financing. BioCentury | Sep 10, 2018. Metabolon stock price, funding rounds, valuation and financials. Metabolon Inc., a medical technology firm that tests how diseases and drugs affect the body, is working on an IPO that could launch in the next couple months, people familiar with the … Metabolon General Information Description. 2. Metabolon, Inc. is the world’s leading life sciences company focused on metabolomics – an integrative, powerful technology for assessing health. S&P 500 0.00%. Metabolon Funding. Metabolon, Inc., a technology company, develops analytical methods and software for biomarker discovery using metabolomics. Rooms Trade App. The company provides biochemical markers and information for understanding biochemical … More. Press Release Metabolomics Market Global Insights and Growing Trend Analysis 2020-2026: Thermo Fisher Scientific, Metabolon, Inc., Bruker Corporation Inc., Trending now. PRIVATE. All times are ET. Strategic News Service has selected Metabolon Inc., the global leader in metabolomics, as a 2016 FiReStarter company to be featured at the 14th Annual Future in Review conference. Trevor Casserly Research Scientist, Research and Discovery at Metabolon, Inc. Raleigh-Durham-Chapel Hill Area 500+ connections Its proprietary platforms and informatics systems are delivering biomarker discoveries, innovative diagnostic tests, breakthroughs in precision medicine, and robust partnerships in genomics-based health initiatives. Metabolon Receives Growth Capital from Pre-IPO Investor GREENWOOD VILLAGE, Colo., Aug 30, 2011 (BUSINESS WIRE) -- Keating Capital, Inc. ( www.KeatingCapital.com ), a pre-IPO investment fund, Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Its Precision Metabolomics ™ is a powerful, patented technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives. Up-to-the-minute news and analysis on deals, markets and finance around the world. Disclaimer. DOW 0.00%. (PRWEB) September 01, 2011 -- Keating Capital, Inc., a pre-IPO investment fund, announced that on August 25, 2011, it made a $4 million investment in the $13 Metabolon has raised $95.40 m in total funding. Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, today announced the close on $72 million in combined debt and equity financing. SEATTLE, WA--(Marketwired - September 01, 2016) - Strategic News Service (SNS) has selected Metabolon Inc., the global leader in metabolomics, as a 2016 FiReStarter company to be featured at the 14th Annual Future in Review (FiRe) conference. Real-time trade and investing ideas on Metabolon, Inc. BOLON from the largest community of traders and investors. NASDAQ 0.00%. FiRe 2016 will take place September 27-30, 2016, at the Stein Eriksen Lodge Deer Valley in Park City, Utah. View Company. Cancer … Michael Rasche is Pres:International Business at Metabolon Inc. See Michael Rasche's compensation, career history, education, & memberships. Developer of analytical methods software designed to use metabolomics to develop precision medicine.